These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 20100965)

  • 1. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
    J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
    Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
    J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
    Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
    Byrski T; Dent R; Blecharz P; Foszczynska-Kloda M; Gronwald J; Huzarski T; Cybulski C; Marczyk E; Chrzan R; Eisen A; Lubinski J; Narod SA
    Breast Cancer Res; 2012 Jul; 14(4):R110. PubMed ID: 22817698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and treatment strategy for triple-negative breast cancer.
    Yamamoto Y; Iwase H
    Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    Jaspers JE; Rottenberg S; Jonkers J
    Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
    Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
    Holánek M; Bílek O; Nenutil R; Kazda T; Selingerová I; Zvaríková M; Palácová M; Krásenská M; Vyzula R; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):31-35. PubMed ID: 31409079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
    Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
    Musolino A; Michiara M; Bella MA; Naldi N; Zanelli P; Bortesi B; Capelletti M; Soldani L; Camisa R; Martella E; Franciosi V; Savi M; Neri TM; Ardizzoni A; Cascinu S
    Tumori; 2005; 91(6):505-12. PubMed ID: 16457150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
    Li M; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Gene; 2016 Jun; 584(1):26-30. PubMed ID: 26956035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.